Download PDF
Semin Respir Crit Care Med 2022; 43(05): 627-634
DOI: 10.1055/s-0042-1753486
Review Article

Current Biologics in Asthma Treatment

Donya Imanirad
1   Department of Allergy, Immunology, Morsani College of Medicine, University of South Florida, Tampa, Florida
,
Farnaz Tabatabaian
2   Division of Allergy and Immunology in Medicine and Pediatrics, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida
› Author Affiliations
› Further Information
   Buy Article Permissions and Reprints

Abstract

Uncontrolled asthma and/or severe asthma causes significant impairments in quality of life and is often a huge health care burden. Monoclonal antibodies have been an important addition to the therapeutic management of patients with moderate to severe asthma who do not respond to conventional asthma management. Currently the majority of Food and Drug Administration (FDA) approved biologics target T2 high inflammation. However, with the expanding knowledge of asthma pathogenesis, novel therapeutics targeting T2 low inflammation are in development. In this article we will focus on the current understanding of T2 inflammation and approved biologics for moderate to severe asthma.

Keywords

biologics - T2 high inflammation - T2 low inflammation - moderate to severe asthma - eosinophilic asthma


Publication History

Article published online:
11 October 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA